Citations

Clear

16280 citation(s) found for "Ha, David R".

African Genetic Similarity Is Associated with Reduced Inflammation and Enhanced Adaptive Immunity in Multiple Myeloma
Pilcher, William , Tang, Hongwei, Ferguson, Katherine, Foltz, Steven , Michaud, Marina E. , Satpathy, Sarthak , Shah, Nishi , Jin, Yuxin , Ohlstrom, Denis, Bakhtiari, Mojtaba , Acharya, Chaitanya R. , Gout, Alexander M. , Keats, Jonathan J. , Dhodapkar, Madhav V. , Avigan, David , Vij, Ravi, Kumar, Shaji , Cho, Hearn Jay , Vlachos, Ioannis S. , Ding, Li , Gnjatic, Sacha , Cole, Craig E. , Nooka, Ajay K. , Lonial, Sagar, Carpten, John, Baughn, Linda B. , Bhasin, Manoj

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033999 | PMID 42832384 Get It

The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
What Happens after an Incidental Thyroid Nodule? Patterns of Thyroid Ultrasound Use and Downstream Evaluation
Larios, Felipe , Vilatuna Andrango, Luis, Borras-Osorio, Mariana , Branda, Megan , Toro-Tobon, David , Cabezas, Esteban , Mateo Chavez, Maria, Claros, Ana Gabriela , Lizarazo Jimenez, Maria, Alzamora, Ivan Mateo , Gomez-Alvarez, Esteban , Al Zahidy, Misk , Fan, Jungwei W, Ponce, Oscar Josue

Mayo Clinic

Thyroid® | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10507256261493769 | PMID 42813606 Get It

Background: Incidental thyroid nodules (ITNs) detected on nonthyroid imaging contribute to thyroid cancer overdiagnosis, largely through downstream evaluation initiated by thyroid ultrasound (TUS). However, TUS follow-up rates for ITNs and their drivers in routine practice remain unclear. We quantified TUS utilization after ITN detection and identified patient, imaging, nodule, and reporting factors associated with this first step in the diagnostic cascade. Methods: We conducted a retrospective cohort study of adults without prior thyroid disease who underwent imaging that incidentally captured the thyroid at Mayo Clinic sites (2017–2023). A validated natural language processing pipeline identified ITNs and extracted nodule characteristics from radiology reports across multiple imaging modalities. The main outcome was the rate of TUS within 180 days after ITN detection. Clinical outcomes, including thyroid biopsy, thyroidectomy, and thyroid cancer diagnosis, were compared between patients who underwent TUS and those who did not. Factors associated with TUS utilization were assessed using multivariable logistic regression with penalized variable selection. Results: Among 115,683 patients who underwent thyroid-capturing imaging, 8426 (7.3%) had an ITN. These patients were predominantly female (64.6%) and White (89.7%), with a mean age of 61.7 years (standard deviation 15.2). Most nodules were detected on computed tomography (80.8%), most commonly from chest imaging (52.3%). Overall, 1677 patients with ITNs (19.9%) underwent TUS. In multivariable analysis, TUS use was independently associated with higher body mass index (odds ratio [OR], 1.20 per 10-unit increase; confidence interval [CI] [1.08–1.33]), nodule size ≥1.5 cm (OR, 1.79; CI [1.52–2.10]), and a radiologist recommendation (OR, 2.51; CI [2.12–2.98]), whereas older age was associated with lower odds of TUS (OR, 0.89 per 10-year increase; CI [0.84–0.93]). Patients undergoing TUS had higher rates of thyroid biopsy, partial thyroidectomy, and total thyroidectomy compared with those without it. All detected thyroid cancers (103 cases) occurred in the TUS group, representing 6.1% of that cohort. Conclusions: One in five patients with ITNs underwent TUS, representing a critical gateway to downstream diagnostic procedures and thyroid cancer detection. Factors associated with TUS utilization highlight opportunities to better define appropriateness of ultrasound after incidental nodule detection and to reduce unnecessary testing and treatment.
Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome
Montes, Daniel, Langenfeld, Hannah E., Hanson, Andrew C., Crowson, Cynthia S. , Patnaik, Mrinal M., Go, Ronald S. , Kalantari, Kambiz , Kusne, Yael, Lasho, Terra, Mangaonkar, Abhishek A. , Olteanu, Horatiu , Reichard, Kaaren K., Sullivan, Megan M. , Viswanatha, David S., Warrington, Kenneth J. , Koster, Matthew J.

Mayo Clinic

ACR Open Rheumatology | September 24, 2026 | Volume: 8 | Issue: 10 | Pages: No page available

10.1002/acr2.90153 | PMID 42782167 Get It

Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors (TNFαi), or interleukin‐1 (IL‐1) or IL‐6 inhibitors were identified. Clinical and biochemical data were recorded for patients at time of targeted therapy initiation, and at 3‐, 6‐, and 12‐month follow‐up time points. Treatment response was labeled as complete response (CR; normalization of C‐reactive protein [CRP], prednisone <10 mg/day, and resolution of disease activity), partial response (PR; >50% improvement in CRP, >50% prednisone dose reduction, improvement or resolution of disease features), treatment failure (TF; worsening CRP, increasing prednisone, worsening of disease features), or no response (not meeting criteria for CR, PR, or TF). Results Overall, 52 patients received an IL‐1i, IL‐6i, or JAKi therapy. At six‐month follow‐up, 3 of 19 IL‐6i patients experienced CR, 4 of 19 experienced PR, and 7 of 19 experienced TF. 2 of 17 patients receiving JAKi experienced CR, 3 of 17 experienced PR, and 6 of 17 experienced TF. No patients receiving IL‐1i or TNFαi experienced CR, and only 1 of 5 IL‐1i patients experienced PR. Among those still receiving biologic therapy at 12 months, only 1 of 11 receiving IL‐6i and 0 of 7 receiving JAKi experienced CR. Conclusion IL‐6i and JAKi therapies demonstrated limited, unsustained efficacy for management of VEXAS syndrome. IL‐1i and TNFαi therapies were not efficacious. Useful application of previously reported treatment response criteria was demonstrated, but future incorporation of hematologic parameters may be beneficial.
PATIENT SATISFACTION FOLLOWING UROLOGY RETURN VISITS BASED ON PROVIDER TYPE
Kahn, Amanda E. , Qosja, Neda, Spaulding, Aaron , Bews, Katie, Cardona, Kathryn, Lee, Yeonsoo Sara , Geldmaker, Laura , McCoy, Katherine , Zhang, Jaine, Thiel, David D. , Kahn, Amanda

Mayo Clinic

Urology Practice | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/upj.0000000000001095 | PMID 42782709 Get It

Clinical and preclinical investigation of the mechanism promoting aura in post-traumatic headache and inhibition of pain-related behavior in mice by onabotulinumtoxinA
Bader, Colin, Haskie, Kaitlyn E., Li, Guohui, Vizin, Robson Cristiano Lillo , Chong, Catherine, Dumkrieger, Gina, Koprusinski, Caroline, Dodick, David W., Navratilova, Edita , Porreca, Frank, Schwedt, Todd J. , Anderson, Trent , Dumkrieger, Gina , Dodick, David W. , Porreca, Frank

Mayo Clinic

Pain | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/j.pain.0000000000004098 | PMID 42775980 Get It

Abstract Post-traumatic headache (PTH) is the most common consequence of mild traumatic brain injury (mTBI) and often resembles migraine. In 20% to 30% of migraine patients, headaches are preceded by aura, transient visual or sensory disturbances, which are caused by cortical spreading depression (CSD) that can induce headache pain. However, whether mTBI promotes the development of aura and CSD and their possible contributions to PTH remains unclear. We examined the incidence of new-onset aura in individuals with PTH who had no history of aura. Thirty-two percent (35/108) developed new aura symptoms within 60 days of injury, suggesting that mTBI can sensitize the cortex to the induction of CSD. To test this, we combined electrophysiology, neuroimaging, and behavioral assays in a mouse model of mTBI-induced PTH. After closed-head mTBI, injured mice exhibited a 160% increase in CSD induction probability (ie, lowered threshold) and became sensitized to CSD induction by brief exposure to stress, a common headache trigger. When evoked optogenetically, CSD produced prolonged periorbital and hind paw allodynia, consistent with headache-like pain. Subcutaneous onabotulinumtoxinA administered to the scalp after mTBI did not alter CSD susceptibility but completely abolished optogenetic CSD-induced allodynia. These findings suggest that mTBI elicits sensitization to CSD induction and promotes the emergence of aura in humans, likely contributing to PTH. It is important that, even after mTBI-induced sensitization, onabotulinumtoxinA decoupled CSD from pain behaviors, suggesting efficacy in treating PTH associated with aura.
Lipoprotein(a) and Incident Venous Thromboembolism
Dreher, Luke A., Abdelnabi, Mahmoud, Ibrahim, Ramzi, VanDolah, Hunter, Farina, Juan M., Simper, David, Lester, Steven J., Alsidawi, Said , Shamoun, Fadi E., Ayoub, Chadi , Arsanjani, Reza, Abdul Nabi, Hussein , Dreher, Luke , Nabi, Hussein Abdul , Abdelnabi, Mahmoud , Ibrahim, Ramzi , Farina, Juan M. , Shamoun, Fadi , Arsanjani, Reza

Mayo Clinic

JAMA Cardiology | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.3964 | PMID 42776511 Get It

This cohort study evaluates the association between measured lipoprotein(a) level and incident venous thromboembolism.
Assessment of Fairness and Bias of an Image-based Surgical Site Infection Detection AI Model
Lee, Frank G. , Choudhary, Ashok , Li-Han, Leo Yan , Dale, Erica L., Bankes, Audrey C , Varghese, Chris , Anderson, Stephanie S., Habermann, Elizabeth B. , Etzioni, David A. , McLaughlin, Sarah A. , Salehinejad, Hojjat , Thiels, Cornelius A. , Varghese, Chris , Habermann, Elizabeth , Dale, Erica , Bankes, Audrey , Choudhary, Ashok , Lee, Frank G

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.22.26363636 Get It

ABSTRACT Background Evaluating fairness in artificial intelligence (AI) is essential before clinical implementation to prevent unintended harm across diverse patient populations. This study assesses performance differences of an image-based surgical site infection (SSI) detection model across age, gender, geography, race, and skin color. Methods Model development/validation study using retrospective, multicenter data across surgical subspecialties from adults who submitted an image of their incision via the electronic health record within 30 days of their procedure between 2019-2024. Area under receiver operating curve (AUROC) was compared by age (<55 vs. ≥55 years old), gender (male vs. female), geography (Rochester, Minnesota vs. Jacksonville, Florida vs. Scottsdale, Arizona vs. regional Minnesota/Wisconsin areas), race (White/Caucasian vs. non-White/Caucasian), and skin color (Fitpatrick I-III vs. IV-VI and Monk A-E vs. F-J). Results Training data contained 13,702 images from 4,274 patients between 2019-2022 (50.1% ≥55 years old; 63.2% female; 91.6% White/Caucasian; 58.5% Rochester, 17.3% Florida, 10.5% Arizona; 96.3% light skin tone), of which 1,348 images (9.8%) had an SSI. No differences in SSI detection existed for age, gender, race, or skin color (AUROC 0.83-0.87, p>0.09), however geographical differences were significant: lowest AUROC 0.83 (95% CI 0.77-0.88) vs. highest AUROC 0.87 (95% CI 0.84-0.89, p=0.01). Temporal validation using 4,242 images from 1,353 patients between 2022-2023 showed intact fairness across subgroups (ΔAUROC ≤0.06) except geography (ΔAUROC ≤0.16). Conclusions The model behaved fairly across age, gender, race, and skin color, however geographical differences persisted. These findings have practical implications underscoring the importance of evaluating bias in clinical AI before deployment.
A Genetic Risk Variant Associated With the Risk of Primary Biliary Cholangitis Is Inherited From Neanderthals
Gerussi, Alessio , Caime, Chiara , Wang, Harold, Cordell, Heather J. , Mells, George , Sandford, Richard N., Jones, David , Hirschfield, Gideon, Siminovitch, Katherine A., Gershwin, M. Eric , Juran, Brian D., Atkinson, Elizabeth J. , Cheung, Angela, Andrade, Mariza de , Baras, Aris, Lazaridis, Konstantinos N. , Asselta, Rosanna , Invernizzi, Pietro , Group, Italian PBC Genetics Study, Jones, David E , Sironi, Manuela , Sankararaman, Sriram , Sandford, Richard , Hirschfield, Gideon M. , Group, Italian PBC Genetics Study

Mayo Clinic

Liver International | September 23, 2026 | Volume: 46 | Issue: 10 | Pages: No page available

10.1111/liv.70868 | PMID 42773620 Get It

ABSTRACT Background Primary Biliary Cholangitis (PBC) is an autoimmune cholangiopathy with polygenic architecture and unknown aetiology. Evidence links Neanderthal‐derived genetic variants to autoimmune conditions; however, their contribution to PBC susceptibility remains unexplored. Objective We investigate whether archaic alleles influence PBC risk. Design Genotype data from four PBC cohorts were analysed: CANUK (4615 cases, 9233 controls), OLD IT (444 cases, 901 controls), NEW IT (255 cases, 579 controls) and MAYO (891 cases, 621 controls). Association testing with 235 592 Neanderthal Informative Markers (NIMs) was performed, adjusting for population stratification. Heritability was estimated using RHE‐mc and temporal haplotype dynamics were assessed using ancient DNA data from Europe and Asia. Results A Neanderthal‐derived variant in TNPO3 (rs12531711), previously reported by Cordell et al. showed strong association in CANUK ( p = 2.04 × 10 −26 ) and replicated across all validation cohorts. This variant functions as an eQTL, upregulating IRF5 and downregulating TNPO3 in blood. It is rare in African populations but common both in Europeans and Asians. Temporal analysis of the haplotype carrying rs12531711 revealed frequency increased substantially during the Bronze Age (5000–3000 BP), rising from 2.0% to 7.7% in Europe and 3.4% to 17.4% in Asia, before stabilizing. Despite this strong single‐variant association, the heritability explained by NIMs was not significantly different from that of non‐NIM variants. Conclusion A Neanderthal‐derived variant contributes to PBC risk and its frequency increased in the Bronze Age, possibly due to pathogen‐driven selection. Archaic introgression overall has limited influence on PBC heritability. Functional studies are needed to elucidate the role of rs12531711.
Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Paolillo, Emily W. , Dhanam, Sreya , Taylor, Jack C. , Sanderson-Cimino, Mark, Fregly, Ray, Saloner, Rowan, Casaletto, Kaitlin B, Kramer, Joel H, Miller, Bruce L, Seeley, William W, Gorno-Tempini, Maria Luisa, Ljubenkov, Peter A. , Rojas, Julio C, Lee, Suzee, Sturm, Virginia, Appleby, Brian, Bayram, Ece, Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S, Vito, Alyssa , Eldaief, Mark, Fields, Julie A. , Ghoshal, Nupur , Huey, Edward D, Irwin, David J, Kantarci, Kejal, Kwan, Justin , Mackenzie, Ian R. , Masdeu, Joseph C, Onyike, Chiadi U, Pantelyat, Alexander, Pascual, Belén , Popli, Tanav, Rascovsky, Katya, Rezaii, Neguine , Scholz, Sonja W. , Snyder, Allison , Tartaglia, Maria Carmela , Traynor, Bryan J, Wong, Bonnie, Kornak, John , Kremers, Walter K. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley F. , Rosen, Howard J, Boxer, Adam L, Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Saloner, Rowan , Casaletto, Kaitlin B. , Kramer, Joel H. , Miller, Bruce L. , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Rojas, Julio C. , Sturm, Virginia E. , Appleby, Brian S. , Day, Gregory S, Vito, Alyssa De, Eldaief, Mark C. , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Masdeu, Joseph, Onyike, Chiadi U. , Popli, Tanav A. , Tartaglia, Maria Carmela , Traynor, Bryan J. , Rosen, Howard J. , Boxer, Adam L.

Mayo Clinic

No container title available | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.26363439 | PMID 42818136 Get It

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility of passive smartphone monitoring in FTLD using a multi-domain mobile assessment platform. Methods: Participants were 567 adults (53% clinically normal, 21% prodromal FTLD, 26% symptomatic FTLD) who completed an in-person study visit and downloaded the ALLFTD Mobile App on their personal smartphones. The app delivered unsupervised cognitive tests and passively collected continuous data on battery percentage (proxy for smartphone use) and step count. Longitudinal follow-up included smartphone monitoring and annual in-person study visits. Primary analyses examined associations between passive smartphone features and markers of disease severity at baseline and longitudinally, and tested whether passive features added incremental value beyond app-based cognitive testing. Results: Passive smartphone features were feasible to collect and showed excellent reliability with <2 weeks of monitoring (ICCs>0.9). Features capturing smartphone use and movement demonstrated sensitivity to gold-standard clinical measures of disease severity both at baseline and longitudinally. A classification model combining passive features, the app-based cognitive composite score, and demographics detected longitudinal functional decline (AUC=0.89); passive features alone (AUC=0.84) performed comparably to a cognitive screener (AUC=0.85). Discussion: Passive smartphone monitoring is a valid, zero-burden measure of disease severity and progression in FTLD that adds modest incremental value beyond app-based cognitive testing. Findings support its use as a scalable digital endpoint in longitudinal FTLD research.
The hippocampus as a latent diffusion engine for memory, perception and cognitive dysfunction
Jones, David T

Mayo Clinic

Brain | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag325 | PMID 43049192 Get It

Abstract The hippocampus is a central cognitive hub whose dysfunction contributes to most neurodegenerative dementias. Despite extensive knowledge of its anatomy, physiology and circuitry, a unifying account that links hippocampal dynamics to cognition and clinical syndromes remains lacking. Drawing on systems neuroscience and recent advances in generative artificial intelligence, we conceptualize the hippocampus as a latent diffusion engine that compresses sensory, interoceptive and cognitive inputs into low-dimensional representations and regenerates percepts, episodic memories and imagined scenes for cortical integration. Travelling waves of cortico-hippocampal oscillations, aligned with large-scale functional gradients, schedule and structure this generative process and organize distributed neural activity into coherent, semantically grounded constructs. We formalize this proposal as stochastic latent oscillatory diffusion (SLOD), a biologically grounded framework that maps hippocampal-cortical computations onto specific anatomical substrates and dynamical processes. While we do not suggest that the hippocampus implements diffusion algorithms per se, we show that its computations can be decomposed into homologous operations including compression, stochastic exploration, conditioning and reconstruction, whose formal structure closely parallels that of latent diffusion models. Finally, we demonstrate how major neurodegenerative dementias, including the Alzheimer’s disease spectrum, dementia with Lewy bodies and frontotemporal dementia, can be understood as selective breakdowns of distinct components of this generative architecture.